CSRP2 promotes cell stemness in head and neck squamous cell carcinoma.
Humans
Squamous Cell Carcinoma of Head and Neck
/ genetics
Carcinoma, Squamous Cell
/ pathology
Head and Neck Neoplasms
/ genetics
Transcription Factors
/ genetics
Phenotype
Cell Line, Tumor
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Cell Movement
Muscle Proteins
/ genetics
Nuclear Proteins
/ genetics
LIM Domain Proteins
/ genetics
CSRP2
epithelial-mesenchymal transition
head and neck squamous cell carcinoma
prognosis
stemness
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
17
06
2023
received:
11
04
2023
accepted:
07
07
2023
medline:
11
8
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Cysteine-rich protein 2 (CSRP2) is discovered as oncogene. The study aims to investigate the clinical significance and potential mechanism of CSRP2 in head and neck squamous cell carcinoma (HNSCC). CSRP2 expression was explored by immunohistochemistry tissue microarrays and Western blotting in HNSCC. The effect of CSRP2 on the cancer stemness and epithelial-to-mesenchymal transition (EMT) of HNSCC cells was investigated by sphere formation, wound healing, and transwell assays. The vitro and vivo experiments revealed that CSRP2 modulated cancer stemness and EMT phenotypes in HNSCC. CSRP2 was overexpressed in HNSCC patients and presented poor prognosis. CSRP2 knockdown inhibited the migration and invasion ability of the HNSCC cells. And CSRP2 expression was closely associated with CSCs markers, EMT-transcription factor, new oncoprotein, and immune checkpoint. The overexpression of CSRP2 indicates poor prognosis and plays a key role in maintaining the cancer cell stemness and EMT.
Sections du résumé
BACKGROUND
Cysteine-rich protein 2 (CSRP2) is discovered as oncogene. The study aims to investigate the clinical significance and potential mechanism of CSRP2 in head and neck squamous cell carcinoma (HNSCC).
METHODS
CSRP2 expression was explored by immunohistochemistry tissue microarrays and Western blotting in HNSCC. The effect of CSRP2 on the cancer stemness and epithelial-to-mesenchymal transition (EMT) of HNSCC cells was investigated by sphere formation, wound healing, and transwell assays. The vitro and vivo experiments revealed that CSRP2 modulated cancer stemness and EMT phenotypes in HNSCC.
RESULTS
CSRP2 was overexpressed in HNSCC patients and presented poor prognosis. CSRP2 knockdown inhibited the migration and invasion ability of the HNSCC cells. And CSRP2 expression was closely associated with CSCs markers, EMT-transcription factor, new oncoprotein, and immune checkpoint.
CONCLUSION
The overexpression of CSRP2 indicates poor prognosis and plays a key role in maintaining the cancer cell stemness and EMT.
Substances chimiques
Transcription Factors
0
CSRP2 protein, human
0
Muscle Proteins
0
Nuclear Proteins
0
LIM Domain Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2161-2172Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Hashim D, Genden E, Posner M, Hashibe M, Boffetta P. Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. Ann Oncol. 2019;30(5):744-756.
Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60-72.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Chinn SB, Darr OA, Owen JH, et al. Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck. 2015;37(3):317-326.
Yu SS, Cirillo N. The molecular markers of cancer stem cells in head and neck tumors. J Cell Physiol. 2020;235(1):65-73.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84.
Celia-Terrassa T, Jolly MK. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb Perspect Med. 2020;10(7):a036905.
Liu S, Shi L, Wang Y, et al. Stabilization of slug by NF-kappaB is essential for TNF-alpha-induced migration and epithelial-mesenchymal transition in head and neck squamous cell carcinoma cells. Cell Physiol Biochem. 2018;47(2):567-578.
Moon JH, Lee SH, Koo BS, et al. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells. Oral Oncol. 2020;111:104948.
Bocci F, Gearhart-Serna L, Boareto M, et al. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci U S A. 2019;116(1):148-157.
Hoffmann C, Mao X, Brown-Clay J, et al. Hypoxia promotes breast cancer cell invasion through HIF-1alpha-mediated up-regulation of the invadopodial actin bundling protein CSRP2. Sci Rep. 2018;8(1):10191.
Weiskirchen R, Moser M, Weiskirchen S, et al. LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J. 2001;359(Pt 3):485-496.
Wei J, Gorman TE, Liu X, et al. Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res. 2005;97(12):1323-1331.
Wang J, Guan X, Zhang Y, et al. Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts. Cell Physiol Biochem. 2018;49(3):869-883.
Chen L, Long X, Duan S, et al. CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-meditated ERK, PAK, and HIPPO signaling pathways. Theranostics. 2020;10(24):11063-11079.
Midorikawa Y, Tsutsumi S, Taniguchi H, et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res. 2002;93(6):636-643.
Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
Wang S, Zhang MJ, Wu ZZ, et al. GSDME is related to prognosis and response to chemotherapy in Oral cancer. J Dent Res. 2022;101:848-858.
Yang LL, Wu L, Yu GT, Zhang WF, Liu B, Sun ZJ. CD317 signature in head and neck cancer indicates poor prognosis. J Dent Res. 2018;97(7):787-794.
Chen L, Huang CF, Li YC, et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018;75(11):2045-2058.
Chen L, Yang QC, Li YC, et al. Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma. Cancer Immunol Res. 2020;8(2):179-191.
Wang Z, Wu VH, Allevato MM, et al. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat Commun. 2019;10(1):5546.
Wang S, Wu ZZ, Zhu SW, et al. CTLA-4 blockade induces tumor pyroptosis via CD8(+) T cells in head and neck squamous cell carcinoma. Mol Ther. 2023;31:2154-2168.
Xiong HG, Li H, Xiao Y, et al. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38(1):278.
Wang Q, Zhao Y, Chen Y, et al. High PD-L1 expression associates with low T-cadherin expression and poor prognosis in human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck. 2023;45(5):1162-1171.
Bian Y, Hall B, Sun ZJ, et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene. 2012;31(28):3322-3332.
Bian Y, Terse A, Du J, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009;69(14):5918-5926.
Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res. 2012;18(19):5304-5313.
Percie du Sert N, Ahluwalia A, Alam S, et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411.
Wang SJ, Wang PZ, Gale RP, et al. Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. Oncotarget. 2017;8(22):35984-36000.
Bhaijee F, Pepper DJ, Pitman KT, Bell D. Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications. Head Neck. 2012;34(6):894-899.
Zhang W, Zhuang N, Liu X, et al. The metabolic regulator Lamtor5 suppresses inflammatory signaling via regulating mTOR-mediated TLR4 degradation. Cell Mol Immunol. 2020;17(10):1063-1076.
Delgado L, Brilhante-Simoes P, Garcez F, Monteiro L, Pires I, Prada J. p-S6 as a prognostic biomarker in canine oral squamous cell carcinoma. Biomolecules. 2022;12(7):935.
Zhu J, Zheng C, Chen J, et al. Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway. Peptides. 2014;52:23-28.
Tao T, Bo L, Li T, et al. High-affinity anti-VISTA antibody protects against sepsis by inhibition of T lymphocyte apoptosis and suppression of the inflammatory response. Mediators Inflamm. 2021;2021:6650329.
Morand GB, Ikenberg K, Vital DG, et al. Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. Head Neck. 2019;41(4):950-958.
Birkeland AC, Owen JH, Prince ME. Targeting head and neck cancer stem cells: current advances and future challenges. J Dent Res. 2015;94(11):1516-1523.
Spencer H, Moshkbouymatin N, Webb WR, Joshi A, D'Souza A. Update on the role of emerging stem cell technology in head and neck medicine. Head Neck. 2021;43(6):1928-1938.
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611-629.
Hoffmann C, Mao X, Dieterle M, et al. CRP2, A new invadopodia Actin bundling factor critically promotes breast cancer cell invasion and metastasis. Oncotarget. 2016;7(12):13688-13705.